8,000 Shares in Protagonist Therapeutics, Inc. $PTGX Purchased by Seven Fleet Capital Management LP

Seven Fleet Capital Management LP acquired a new position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 8,000 shares of the company’s stock, valued at approximately $699,000.

A number of other hedge funds also recently bought and sold shares of PTGX. Farther Finance Advisors LLC increased its position in shares of Protagonist Therapeutics by 110.6% in the fourth quarter. Farther Finance Advisors LLC now owns 297 shares of the company’s stock worth $26,000 after acquiring an additional 156 shares in the last quarter. Greenline Wealth Management LLC purchased a new stake in shares of Protagonist Therapeutics in the 4th quarter valued at approximately $27,000. EverSource Wealth Advisors LLC lifted its position in shares of Protagonist Therapeutics by 138.9% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 540 shares of the company’s stock valued at $36,000 after acquiring an additional 314 shares in the last quarter. Hantz Financial Services Inc. boosted its stake in Protagonist Therapeutics by 222.4% in the 4th quarter. Hantz Financial Services Inc. now owns 951 shares of the company’s stock worth $83,000 after purchasing an additional 656 shares during the period. Finally, Canton Hathaway LLC acquired a new position in Protagonist Therapeutics in the 4th quarter worth approximately $87,000. 98.63% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts have issued reports on PTGX shares. Barclays boosted their target price on shares of Protagonist Therapeutics from $113.00 to $119.00 and gave the company an “overweight” rating in a research note on Thursday, March 19th. Wall Street Zen upgraded Protagonist Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Saturday, May 9th. Johnson Rice reissued a “buy” rating on shares of Protagonist Therapeutics in a research report on Wednesday, March 18th. JPMorgan Chase & Co. increased their price objective on Protagonist Therapeutics from $95.00 to $106.00 and gave the stock an “overweight” rating in a research note on Thursday, March 19th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Protagonist Therapeutics in a research report on Friday, May 15th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Protagonist Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $115.21.

Insiders Place Their Bets

In related news, insider Arturo Md Molina sold 15,000 shares of the stock in a transaction on Thursday, March 26th. The stock was sold at an average price of $104.79, for a total transaction of $1,571,850.00. Following the completion of the sale, the insider directly owned 84,115 shares in the company, valued at approximately $8,814,410.85. This trade represents a 15.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Dinesh V. Ph D. Patel sold 75,000 shares of Protagonist Therapeutics stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $100.12, for a total value of $7,509,000.00. Following the sale, the chief executive officer directly owned 523,478 shares of the company’s stock, valued at approximately $52,410,617.36. The trade was a 12.53% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 272,345 shares of company stock valued at $27,676,386 in the last three months. Company insiders own 5.19% of the company’s stock.

Protagonist Therapeutics Stock Performance

Protagonist Therapeutics stock opened at $112.86 on Friday. The firm has a market cap of $7.26 billion, a PE ratio of -62.35 and a beta of 1.85. The firm’s 50 day moving average price is $102.38 and its two-hundred day moving average price is $93.88. Protagonist Therapeutics, Inc. has a twelve month low of $49.38 and a twelve month high of $114.49.

Protagonist Therapeutics (NASDAQ:PTGX) last issued its earnings results on Tuesday, May 5th. The company reported $0.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.55. Protagonist Therapeutics had a negative net margin of 154.88% and a negative return on equity of 17.76%. The company had revenue of $56.37 million during the quarter, compared to analyst estimates of $11.70 million. Equities analysts anticipate that Protagonist Therapeutics, Inc. will post 2.93 EPS for the current fiscal year.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral ?4?7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.